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Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse reaction to neuroleptics, which is
characterized by hyperthermia, extrapyramidal symptoms, altered consciousness and autonomic dysfunction.
Although NMS is most commonly induced by the high-potency neuroleptics, its development has also been
associated with the use of non-neuroleptic agents that block central dopamine pathways. A 68-year-old man
with generalized anxiety disorder and depressive symptoms presented at the emergency department (ED)
with high fever, tremor, muscle rigidity, rhabdomyolysis and altered mental status. NMS was considered to
have been caused by the recent addition and subsequent dose increase in his treatment regimen of venlafaxine,
a serotonin norepinephrine reuptake inhibitor. He was successfully treated with bromocriptine, lorazepam,
and fluid hydration in the ED and intensive care unit. [J Formos Med Assoc 2006;105(1):90–93]
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Neuroleptic malignant syndrome (NMS) is a rare
complication of treatment with neuroleptic drugs.
Few cases of NMS have been reported to be caused
by use of selective serotonin reuptake inhibitor
(SSRI) or serotonin norepinephrine reuptake in-
hibitor (SNRI).1–3 We report a 68-year-old man with
generalized anxiety disorder who developed acute
onset of hyperthermia, altered mental status,
rigidity, tremor and rhabdomyolysis 9 days
after treatment with venlafaxine, a dual SNRI. The
clinical symptoms of NMS are described, in close
relation to the initiation of new treatment with
venlafaxine. The possible pathologic mechanism
of NMS in this patient is discussed.
Case Report
A 68-year-old man was sent to the emergency room
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after suddenly developing symptoms of high
fever, tremor and altered mental status. A DSM-IV
(Diagnostic and Statistical Manual of Mental
Disorders, 4th edition) axis I diagnosis of general-
ized anxiety disorder with depressive symptoms not
fulfilling the criteria of major depression was first
made 6 years prior to admission. He had been treat-
ed with propranolol, buspirone, clonazepam, tra-
zodone and fluoxetine. In the 2 months prior to
admission, his depressive symptoms had exacer-
bated and he had involuntary movements of four
limbs and difficulty in initiating walking. On a visit
to the psychiatric outpatient clinic 9 days prior to
this admission, amantadine 50 mg three times
daily was added under the tentative impression of
Parkinsonism, and fluoxetine was changed to ven-
lafaxine 75 mg once daily. One week later, aman-
tadine and venlafaxine doses were increased to 100
mg and 75 mg twice daily, respectively.
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Discussion
NMS, which is thought to be an idiosyncratic
drug reaction, is a rare but potentially lethal com-
plication of treatment with neuroleptics. Accord-
ing to one theory, decreased dopamine activity
in the central nervous system (CNS), either from
blockade of dopamine D2-receptors or decreased
availability of dopamine itself, plays a role in
the pathogenesis of NMS.4 Manifestations of
NMS may include autonomic instability, hyper-
pyrexia, altered mental status, and extrapyramidal
reactions.5 The appearance of these symptoms,
especially extrapyramidal reactions in patients re-
ceiving antipsychotic drugs, should alert physi-
cians to include NMS in the differential diagno-
sis. Although extrapyramidal reactions or NMS
are most likely to be associated with the use of
high-potency neuroleptics, these uncommon
side effects have been reported to be associated
with SSRI use.1,2 Serotonin’s inhibitory action on
SSRI-induced extrapyramidal dopamine activity
has been proposed to contribute to the etiology.6
Some authors have also hypothesized that indi-
viduals who develop extrapyramidal symptoms
after SSRI use may actually have preclinical Par-
kinsonism.7,8
Venlafaxine is an SNRI. There have been an in-
creasing number of reports of extrapyramidal re-
actions in association with venlafaxine.9–11 It has
been reported to induce NMS when combined with
trifluoperazine.3 Cassidy and O’Kearne considered
that absence of altered sensorium and a relatively
benign course, as in the above-reported patient,
are more likely to be serotonin syndrome than
NMS.12
NMS and serotonin syndrome are difficult to
differentiate because of their overlapping clinical
features. The diagnostic criteria for serotonin syn-
drome as proposed by Sternbach are: recent change
of a potent serotonin agent; no history of sub-
stance abuse or infectious or metabolic disease;
absence of treatment with any antipsychotic
drug; and * 3 of the following symptoms:
(1) change in the finding of the mental status,
(2) agitation, (3) myoclonus, (4) hyperreflexia,
Initial assessment on arrival at the emergency
department revealed that the patient was obtund-
ed and disorientated. His body temperature was
39.7$C, pulse rate was 142 bpm, respiratory rate
was 30/min, and blood pressure was 162/92
mmHg. Neurologic examination showed mild neck
stiffness without meningism, normal deep tendon
reflexes, extreme limb tremors, and cogwheel
rigidity.
Biochemical measures were normal except for
increased serum creatine kinase (CK) (1122 U/L;
normal, 38–160 U/L), aspartate transaminase
(58 U/L; normal, 5–31 U/L) and alanine trans-
aminase (69 U/L; normal 0–41 U/L) levels. White
blood cell (WBC) count was 6.27 = 109/L with
90.4% neutrophils. Brain computed tomography
revealed no abnormalities. Lumbar puncture
showed normal intracranial pressure (opening
pressure, 120 mmH2O; closing pressure, 85
mmH2O) without the presence of pleocytosis.
His temperature elevated to 41.5$C despite
receiving fluid hydration (0.9% sodium chloride)
and antipyretics with oral acetaminophen 500 mg,
intramuscular ketorolac 30 mg, and intravenous
lysine acetylsalicylate 0.9 g. NMS was diagnosed
and the suspected offending drug, venlafaxine, was
discontinued. Bromocriptine 2.5 mg twice a day
was given. Amantadine and other anxiolytics and
antidepressants were maintained after neurologic
and psychiatric consultations. Severe limb trem-
ors and muscle rigidity were noticed and showed
dramatic response to intravenous administration
of lorazepam 2 mg. He was then admitted to the
intensive care unit (ICU) for further care.
After ICU admission, fluid hydration, urine
alkalization, and other supportive treatments were
given. CK level was 25,934 U/L and WBC count
was 12.25 = 109/L with 88.0% neutrophils on the
next day, but these elevated laboratory values de-
clined thereafter. Tremors and rigidity improved
after admission. The septic workup yielded nega-
tive results. He was afebrile 3 days later and his
level of consciousness returned to his previous
condition. He was then transferred to a regular
medical ward and was free of symptoms at dis-
charge 12 days later.
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(5) diaphoresis, (6) shivering, (7) tremor,
(8) diarrhea, (9) uncoordination, and (10)
fever.13 Serotonin syndrome has been reported to
be induced by the use of venlafaxine in combina-
tion with monoamine oxidase inhibitors such as
tranylcypromine or phenelzine.14–16 Isolated and
even low-dose venlafaxine-induced serotonin syn-
drome has been reported.17,18 Although serotonin
syndrome has been increasingly recognized as
a possible adverse event in patients who receive
SNRIs like venlafaxine, it is also possible that NMS
may occur through their serotonergic inhibition
of central dopaminergic activity, a mechanism sim-
ilar to extrapyramidal adverse drug reactions.
The differential diagnosis of NMS should in-
clude malignant hyperthermia (MH), which is
another important cause of drug-induced fever.
Although both MH and NMS are characterized by
hyperthermia, rhabdomyolysis, tachypnea, con-
sciousness disturbances, and acute renal failure,
MH is now referred to as a genetic disease of the
skeletal muscle triggered on exposure to volatile
anesthetic agents or depolarizing muscle relaxants.19
Our patient shared many overlapping features
of drug-induced fever like serotonin syndrome and
MH, but he did not receive any volatile anesthet-
ics or succinylcholine, and the relatively gradual
onset and severe clinical manifestations favored a
diagnosis of NMS rather than serotonin syndrome.
Based on these considerations, the patient was di-
agnosed with NMS rather than other drug-induced
fever due to the presence of extrapyramidal symp-
toms with severe rigidity, severe hyperthermia,
rhabdomyolysis with elevated CK, leukocytosis
with abnormal liver function, and altered mental
status.
There are some diagnostic “weak points” in the
implication of NMS. The lack of uniformly accept-
ed diagnostic criteria makes the diagnosis of
drug-induced NMS more difficult.20 Such diagno-
sis of drug-induced fever can only be established
by withdrawal of the drug and subsequent re-
challenge, which would be an unethical practice.
Further study is needed to accurately and precisely
assess the risk of adverse drug reactions and drug-
drug interactions with novel antidepressants.
In summary, the use of venlafaxine may be
implicated in the development of NMS in patients
with clinical manifestations of Parkinsonism,
possibly due to its serotonergic inhibition of the
central dopaminergic system. Greater awareness of
this potential side effect may facilitate early recog-
nition and treatment to decrease its morbidity.
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